The DOI matches its Crossref record; 58 of the 58 references it cites were found in a registry or an index.
Targeting tumor-associated macrophages and granulocytic myeloid-derived suppressor cells augments PD-1 blockade in cholangiocarcinoma
Open accessAbstract
Figure 1.TAMs are the predominant source of PD-L1 in CCA.(A) Representative images (left and middle panels) of PD-L1 (brown staining, black arrowhead) plus CD68 (red staining, red arrowhead) coimmunostaining (n = 33) and PD-L1 (brown staining) plus CK-19 (red staining) coimmunostaining (n = 18) in human resected CCA specimens.Percentage of patients with positive PD-L1/CD68 costaining and PD-L1/CK19 costaining, respectively (right panel).Scale bars: 40 μm.(B) Histograms show expression of PD-L1 + macrophages in human CCA tumors.(C-F) Flow cytometry analysis of normal WT mouse livers (from WT mice without tumors) as well as adjacent livers and tumors of mice 28 days after orthotopic implantation of 1 × 10 6 SB (murine CCA) cells.(C) Percentage of PD-L1 + macrophages (Mφ) of total macrophages (CD45 + CD11b + F4/80 + ) in WT mouse normal liver, tumor-adjacent liver, or tumor.Fluorescence Minus One (FMO) controls were used for each independent experiment to establish gates (See Supplemental Figure 1A for gating strategy) (n ≥ 8).Representative histograms show expression of PD-L1 + macrophages.(D) Percentage of CD206 + TAMs (left panel) and PD-L1 + CD206 + TAMs (middle panel) of F4/80 int macrophages (CD45 + CD11b + F4/80 int ) in WT mouse liver, tumor-adjacent liver, or tumor.Representative contour plots (right panel) show CD206 and PD-L1 expression of F4/80 int macrophages (n ≥ 7).(E) Percentage of PD-L1 + CD206 -macrophages or PD-L1 + CD206 + macrophages (CD11b + F4/80 + ) of CD45 + cells from SB tumors (n = 28).(F) Percentage of PD-L1 expression in myeloid cells from SB tumors.Macrophages, CD45 + PD-L1 + CD11b + F4/80 + ; MDSCs, CD45 + PD-L1 + CD11c -CD11b + F4/80 -GR-1 + ; DCs, CD45 + PD-L1 + CD11c hi ; (n = 11).Data are represented as mean ± SD.Unpaired Student's t test (E) and 1-way ANOVA with Bonferroni's post hoc test (C, D, and F) were used.*P < 0.05; **P < 0.01; ***P < 0.001.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Comprehensive Integration of Single-Cell Data
Stuart, T., Butler, A., Hoffman, P., Hafemeister, C., Papalexi, E., Mauck, W. M., Hao, Y., Stoeckius, M., Smibert, P., & Satija, R. (2019) · Cell · doi:10.1016/j.cell.2019.05.031 · Cited by 15,453
Integrating single-cell transcriptomic data across different conditions, technologies, and species
Butler, A., Hoffman, P., Smibert, P., Papalexi, E., & Satija, R. (2018) · Nature Biotechnology · doi:10.1038/nbt.4096 · Cited by 13,174
Myeloid-derived-suppressor cells as regulators of the immune system
Gabrilovich, D. I., & Nagaraj, S. (2009) · Nature Reviews Immunology · doi:10.1038/nri2506 · Cited by 6,753
Scenic: single-cell regulatory network inference and clustering.
Aibar, S., González-Blas, C. B., Moerman, T., Huynh-Thu, V. A., Imrichova, H., Hulselmans, G., Rambow, F., Marine, J.-C., Geurts, P., Aerts, J., et al. (2017) · Nature Methods · doi:10.1038/nmeth.4463 · Cited by 6,520
Understanding the tumor immune microenvironment (TIME) for effective therapy
Binnewies, M., Roberts, E. W., Kersten, K., Chan, V., Fearon, D. F., Merad, M., Coussens, L. M., Gabrilovich, D. I., Ostrand-Rosenberg, S., Hedrick, C. C., et al. (2018) · Nature Medicine · doi:10.1038/s41591-018-0014-x · Cited by 6,145
Tumor-associated B7-H1 promotes T-cell apoptosis: A potential mechanism of immune evasion
Dong, H., Strome, S. E., Salomao, D. R., Tamura, H., Hirano, F., Flies, D. B., Roche, P. C., Lu, J., Zhu, G., Tamada, K., et al. (2002) · Nature Medicine · doi:10.1038/nm730 · Cited by 5,025
Self-citationCisplatin plus Gemcitabine versus Gemcitabine for Biliary Tract Cancer
Valle, J., Wasan, H., Palmer, D. H., Cunningham, D., Anthoney, A., Maraveyas, A., Madhusudan, S., Iveson, T., Hughes, S., Pereira, S. P., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa0908721 · Cited by 4,406
Tumor-Associated Macrophages: From Mechanisms to Therapy
Noy, R., & Pollard, J. W. (2014) · Immunity · doi:10.1016/j.immuni.2014.06.010 · Cited by 4,089
Tumour-associated macrophages as treatment targets in oncology
Mantovani, A., Marchesi, F., Malesci, A., Laghi, L., & Allavena, P. (2017) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2016.217 · Cited by 4,033
Coordinated regulation of myeloid cells by tumours
Gabrilovich, D. I., Ostrand-Rosenberg, S., & Bronte, V. (2012) · Nature Reviews Immunology · doi:10.1038/nri3175 · Cited by 3,544
Murray, P. J. (2017) · Annual Review of Physiology · doi:10.1146/annurev-physiol-022516-034339 · Cited by 2,981
Macrophages: Obligate Partners for Tumor Cell Migration, Invasion, and Metastasis
Condeelis, J., & Pollard, J. W. (2006) · Cell · doi:10.1016/j.cell.2006.01.007 · Cited by 2,695
Dong, H., Zhu, G., Tamada, K., & Chen, L. (1999) · Nature Medicine · doi:10.1038/70932 · Cited by 2,496
Self-citationCSF-1R inhibition alters macrophage polarization and blocks glioma progression
Pyonteck, S. M., Akkari, L., Schuhmacher, A. J., Bowman, R. L., Sevenich, L., Quail, D. F., Olson, O. C., Quick, M. L., Huse, J. T., Teijeiro, V., et al. (2013) · Nature Medicine · doi:10.1038/nm.3337 · Cited by 2,463
Noman, M. Z., Desantis, G., Janji, B., Hasmim, M., Karray, S., Dessen, P., Bronte, V., & Chouaib, S. (2014) · Journal of Experimental Medicine · doi:10.1084/jem.20131916 · Cited by 2,166
Targeting macrophages: therapeutic approaches in cancer
Cassetta, L., & Pollard, J. W. (2018) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2018.169 · Cited by 2,048
The diverse functions of the PD1 inhibitory pathway
Sharpe, A. H., & Pauken, K. E. (2018) · Nature Reviews Immunology · doi:10.1038/nri.2017.108 · Cited by 1,971
Myeloid-Derived Suppressor Cells
Gabrilovich, D. I. (2017) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-16-0297 · Cited by 1,882
Myeloid-derived suppressor cells coming of age
Veglia, F., Perego, M., & Gabrilovich, D. (2018) · Nature Immunology · doi:10.1038/s41590-017-0022-x · Cited by 1,767
Cholangiocarcinoma — evolving concepts and therapeutic strategies
Ilyas, S. I., Khan, S. A., Hallemeier, C. L., Kelley, R. K., & Gores, G. J. (2018) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2017.157 · Cited by 1,626
Self-citationBoring, L., Gosling, J., Chensue, S. W., Kunkel, S. L., Farese, R. V., Broxmeyer, H. E., & Charo, I. F. (1997) · Journal of Clinical Investigation · doi:10.1172/jci119798 · Cited by 1,096
Bayne, L. J., Beatty, G. L., Jhala, N., Clark, C. E., Rhim, A. D., Stanger, B. Z., & Vonderheide, R. H. (2012) · Cancer Cell · doi:10.1016/j.ccr.2012.04.025 · Cited by 947 · cited 1×
“Indeed, the TIME of highly lethal, difficult-totreat, desmoplastic malignancies such as CCA or pancreatic ductal adenocarcinoma has an abundance of immunosuppressive myeloid cells including tumor-associated macrophages (TAMs) and myeloid-derived suppressor cells (MDSCs) (9, 10).”
BackgroundTumor Cell Biodiversity Drives Microenvironmental Reprogramming in Liver Cancer
Ma, L., Hernandez, M. O., Zhao, Y., Mehta, M., Tran, B., Kelly, M., Rae, Z., Hernandez, J. M., Davis, J. L., Martin, S. P., et al. (2019) · Cancer Cell · doi:10.1016/j.ccell.2019.08.007 · Cited by 844
Zhu, Y., Herndon, J. M., Sojka, D. K., Kim, K.-W., Knolhoff, B. L., Zuo, C., Cullinan, D. R., Luo, J., Bearden, A. R., Lavine, K. J., et al. (2017) · Immunity · doi:10.1016/j.immuni.2017.07.014 · Cited by 801
Disruption of CXCR2-Mediated MDSC Tumor Trafficking Enhances Anti-PD1 Efficacy
Highfill, S. L., Cui, Y., Giles, A. J., Smith, J. P., Zhang, H., Morse, E., Kaplan, R. N., & Mackall, C. L. (2014) · Science Translational Medicine · doi:10.1126/scitranslmed.3007974 · Cited by 767 · cited 2×
“MDSCs also have a significant association with poor patient outcomes as well as chemotherapy and immunotherapy resistance (35, 47).”
BackgroundGoswami, S., Sahai, E., Wyckoff, J. B., Cammer, M., Cox, D., Pixley, F. J., Stanley, E. R., Segall, J. E., & Condeelis, J. S. (2005) · Cancer Research · doi:10.1158/0008-5472.can-04-1853 · Cited by 738
Burden of Digestive Diseases in the United States Part III: Liver, Biliary Tract, and Pancreas
Everhart, J. E., & Ruhl, C. E. (2009) · Gastroenterology · doi:10.1053/j.gastro.2009.02.038 · Cited by 710
Kumar, V., Donthireddy, L., Marvel, D., Condamine, T., Wang, F., Lavilla-Alonso, S., Hashimoto, A., Vonteddu, P., Behera, R., Goins, M. A., et al. (2017) · Cancer Cell · doi:10.1016/j.ccell.2017.10.005 · Cited by 653
Global trends in mortality from intrahepatic and extrahepatic cholangiocarcinoma
Bertuccio, P., Malvezzi, M., Carioli, G., Hashim, D., Boffetta, P., El-Serag, H. B., La Vecchia, C., & Negri, E. (2019) · Journal of Hepatology · doi:10.1016/j.jhep.2019.03.013 · Cited by 648
Host expression of PD-L1 determines efficacy of PD-L1 pathway blockade–mediated tumor regression
Lin, H., Wei, S., Hurt, E. M., Green, M. D., Zhao, L., Vatan, L., Szeliga, W., Herbst, R., Harms, P. W., Fecher, L. A., et al. (2018) · Journal of Clinical Investigation · doi:10.1172/jci96113 · Cited by 584
Wang, J., & Kubes, P. (2016) · Cell · doi:10.1016/j.cell.2016.03.009 · Cited by 537
Self-citationAlshetaiwi, H., Pervolarakis, N., McIntyre, L. L., Ma, D., Nguyen, Q., Rath, J. A., Nee, K., Hernandez, G., Evans, K., Torosian, L., et al. (2020) · Science Immunology · doi:10.1126/sciimmunol.aay6017 · Cited by 537
PD-L1 on host cells is essential for PD-L1 blockade–mediated tumor regression
Tang, H., Liang, Y., Anders, R. A., Taube, J. M., Qiu, X., Mulgaonkar, A., Liu, X., Harrington, S. M., Guo, J., Xin, Y., et al. (2018) · Journal of Clinical Investigation · doi:10.1172/jci96061 · Cited by 524
Self-citationMacDonald, K. P. A., Palmer, J. S., Cronau, S., Seppanen, E., Olver, S., Raffelt, N. C., Kuns, R., Pettit, A. R., Clouston, A., Wainwright, B., et al. (2010) · Blood · doi:10.1182/blood-2010-02-266296 · Cited by 506
LXR/ApoE Activation Restricts Innate Immune Suppression in Cancer
Tavazoie, M. F., Pollack, I., Tanqueco, R., Ostendorf, B. N., Reis, B. S., Gonsalves, F. C., Kurth, I., Andreu-Agullo, C., Derbyshire, M. L., Posada, J., et al. (2018) · Cell · doi:10.1016/j.cell.2017.12.026 · Cited by 476
Tumour and host cell PD-L1 is required to mediate suppression of anti-tumour immunity in mice
Lau, J., Cheung, J., Navarro, A., Lianoglou, S., Haley, B., Totpal, K., Sanders, L., Koeppen, H., Caplazi, P., McBride, J., et al. (2017) · Nature Communications · doi:10.1038/ncomms14572 · Cited by 365
High-dimensional analysis of the murine myeloid cell system
Becher, B., Schlitzer, A., Chen, J., Mair, F., Sumatoh, H. R., Teng, K. W. W., Low, D., Ruedl, C., Riccardi-Castagnoli, P., Poidinger, M., et al. (2014) · Nature Immunology · doi:10.1038/ni.3006 · Cited by 357
Cytofkit: A Bioconductor Package for an Integrated Mass Cytometry Data Analysis Pipeline
Chen, H., Lau, M. C., Wong, M. T., Newell, E. W., Poidinger, M., & Chen, J. (2016) · PLOS Computational Biology · doi:10.1371/journal.pcbi.1005112 · Cited by 355
Frigola, X., Inman, B. A., Lohse, C. M., Krco, C. J., Cheville, J. C., Thompson, R. H., Leibovich, B., Blute, M. L., Dong, H., & Kwon, E. D. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-0250 · Cited by 345
Self-citationTumor-derived exosomes modulate PD-L1 expression in monocytes
Haderk, F., Schulz, R., Iskar, M., Cid, L. L., Worst, T., Willmund, K. V., Schulz, A., Warnken, U., Seiler, J., Benner, A., et al. (2017) · Science Immunology · doi:10.1126/sciimmunol.aah5509 · Cited by 298
Zhang, H., Ye, Y.-L., Li, M.-X., Ye, S.-B., Huang, W.-R., Cai, T.-T., He, J., Peng, J.-Y., Duan, T.-H., Cui, J., et al. (2017) · Oncogene · doi:10.1038/onc.2016.367 · Cited by 278
Sierro, F., Evrard, M., Rizzetto, S., Melino, M., Mitchell, A. J., Florido, M., Beattie, L., Walters, S. B., Tay, S. S., Lu, B., et al. (2017) · Immunity · doi:10.1016/j.immuni.2017.07.018 · Cited by 252
Yes-associated protein mediates immune reprogramming in pancreatic ductal adenocarcinoma
Murakami, S., Shahbazian, D., Surana, R., Zhang, W., Chen, H., Graham, G. T., White, S. M., Weiner, L. M., & Yi, C. (2017) · Oncogene · doi:10.1038/onc.2016.288 · Cited by 215
Guo, Q., Furuta, K., Lucien, F., Gutierrez Sanchez, L. H., Hirsova, P., Krishnan, A., Kabashima, A., Pavelko, K. D., Madden, B., Alhuwaish, H., et al. (2019) · Journal of Hepatology · doi:10.1016/j.jhep.2019.07.019 · Cited by 181
Self-citationZhu, Y., Herndon, J. M., Sojka, D. K., Kim, K.-W., Knolhoff, B. L., Zuo, C., Cullinan, D. R., Luo, J., Bearden, A. R., Lavine, K. J., et al. (2017) · Immunity · doi:10.1016/j.immuni.2017.08.018 · Cited by 180
The Role of Myeloid-Derived Suppressor Cells in Patients with Solid Tumors: A Meta-Analysis
Zhang, S., Ma, X., Zhu, C., Liu, L., Wang, G., & Yuan, X. (2016) · PLOS ONE · doi:10.1371/journal.pone.0164514 · Cited by 180
Pencheva, N., Buss, C. G., Posada, J., Merghoub, T., & Tavazoie, S. F. (2014) · Cell · doi:10.1016/j.cell.2014.01.038 · Cited by 175 · cited 1×
“ApoE is a secreted protein implicated in lipoprotein metabolism and inhibition of metastatic progression in melanoma (40).”
BackgroundYamada, D., Ilyas, S. I., Razumilava, N., Bronk, S. F., Davila, J. I., Champion, M. D., Borad, M. J., Bezerra, J. A., Chen, X., & Gores, G. J. (2015) · Hepatology · doi:10.1002/hep.27687 · Cited by 145
Self-citationde Planell-Saguer, M., Rodicio, M., & Mourelatos, Z. (2010) · Nature Protocols · doi:10.1038/nprot.2010.62 · Cited by 141
NUAK2 is a critical YAP target in liver cancer
Yuan, W.-C., Pepe-Mooney, B. J., Galli, G. G., Dill, M. T., Huang, H., Hao, M., Wang, Y., Liang, H., Calogero, R., & Camargo, F. D. (2018) · Nature Communications · doi:10.1038/s41467-018-07394-5 · Cited by 135
Wong, M. T., Chen, J., Narayanan, S., Lin, W., Anicete, R., Tan, H. K. K., de Lafaille, M. A. C., Poidinger, M., & Newell, E. W. (2015) · Cell Reports · doi:10.1016/j.celrep.2015.05.022 · Cited by 131
Manthey, C. L., Johnson, D. L., Illig, C. R., Tuman, R. W., Zhao, Z., Baker, J. F., Chaikin, M. A., Donatelli, R. R., Franks, C. F., Zeng, L., et al. (2009) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-09-0255 · Cited by 115
Liu, F., Li, X., Lu, C., Bai, A., Bielawski, J., Bielawska, A. E., Marshall, B., Schoenlein, P. V., Lebedyeva, I., & Liu, K. (2016) · Oncotarget · doi:10.18632/oncotarget.13438 · Cited by 97
YAP-associated chromosomal instability and cholangiocarcinoma in mice
Rizvi, S. H., Fischbach, S. R., Bronk, S. F., Hirsova, P., Krishnan, A., Dhanasekaran, R., Smadbeck, J. B., Smoot, R. L., Vasmatzis, G., & Gores, G. J. (2017) · Oncotarget · doi:10.18632/oncotarget.23638 · Cited by 75
Self-citationSideras, K., de Man, R. A., Harrington, S. M., Polak, W. G., Zhou, G., Schutz, H. M., Pedroza‐González, A., Biermann, K., Mancham, S., Hansen, B. E., et al. (2019) · Scientific Reports · doi:10.1038/s41598-019-47235-z · Cited by 60
Self-citationLiu, X., Gibbons, R., Harrington, S. M., Krco, C. J., Markovic, S. N., Kwon, E. D., & Dong, H. (2013) · OncoImmunology · doi:10.4161/onci.23972 · Cited by 53
Self-citationCirculating myeloid-derived suppressor cells in patients with pancreatic cancer
Xu, X., Hu, J., Wang, M., Peng, F., Tian, R., Guo, X., Xie, Y., & Qin, R. (2016) · Hepatobiliary & pancreatic diseases international · doi:10.1016/s1499-3872(15)60413-1 · Cited by 50
S100A4 Protects Myeloid-Derived Suppressor Cells from Intrinsic Apoptosis via TLR4–ERK1/2 Signaling
Li, Q., Dai, C., Xue, R., Wang, P., Chen, L., Han, Y., Erben, U., & Qin, Z. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.00388 · Cited by 36
Cited by
Immunosuppressive cells in cancer: mechanisms and potential therapeutic targets
Tie, Y., Tang, F., Wei, Y.-Q., & Wei, X.-W. (2022) · Journal of Hematology & Oncology · doi:10.1186/s13045-022-01282-8 · Cited by 591
Tumor‐associated macrophages in liver cancer: From mechanisms to therapy
Cheng, K., Cai, N., Zhu, J., Yang, X., Liang, H., & Zhang, W. (2022) · Cancer Communications · doi:10.1002/cac2.12345 · Cited by 460
Tumor heterogeneity reshapes the tumor microenvironment to influence drug resistance
Zhang, A., Miao, K., Sun, H., & Deng, C.-X. (2022) · International Journal of Biological Sciences · doi:10.7150/ijbs.72534 · Cited by 352
Gut Microbiome Directs Hepatocytes to Recruit MDSCs and Promote Cholangiocarcinoma
Zhang, Q., Ma, C., Duan, Y., Heinrich, B., Rosato, U., Diggs, L. P., Ma, L., Roy, S., Fu, Q., Brown, Z. J., et al. (2021) · Cancer Discovery · doi:10.1158/2159-8290.cd-20-0304 · Cited by 257
Metabolic reprogramming in the tumor microenvironment of liver cancer
Lin, J., Rao, D., Zhang, M., & Gao, Q. (2024) · Journal of Hematology & Oncology · doi:10.1186/s13045-024-01527-8 · Cited by 251
Metadata
- Authors
- Loeuillard, E., Yang, J., Buckarma, E., Wang, J., Liu, Y., Conboy, C., Pavelko, K. D., Li, Y., O’Brien, D., Wang, C., Graham, R. P., Smoot, R. L., Dong, H., & Ilyas, S.
- Venue
- Journal of Clinical Investigation
- Published
- 2020-09-14
- Volume
- 130
- Issue
- 10
- Pages
- 5380-5396
- ISSN
- 0021-9738 (ISSN-L)
- 1558-8238
- OpenAlex
- W3043690500
- Cited by
- 369
- References
- 58
- FWCI
- 13.95
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.